Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (BLCO) delivers essential vision care solutions through its innovative contact lenses, surgical technologies, and ophthalmic pharmaceuticals. This news hub provides investors and industry professionals with timely updates on the company’s latest developments across all business segments.
Track official press releases, financial announcements, and strategic initiatives in one centralized location. Our curated collection includes updates on product approvals, earnings results, research breakthroughs, and partnerships that shape the future of eye health innovation.
Discover how BLCO’s three core segments – Vision Care, Surgical, and Ophthalmic Pharmaceuticals – continue advancing ocular treatment standards worldwide. The company’s commitment to clinical excellence and regulatory compliance remains central to all updates shared here.
Bookmark this page for direct access to verified information about Bausch + Lomb’s market activities. Check regularly for new developments impacting the vision care industry and BLCO’s position as a leader in medical eye solutions.
Bausch + Lomb (NYSE/TSX: BLCO) has received Health Canada approval for its new enVista® Envy™ intraocular lens (IOL), marking the first global regulatory approval of this product. The enVista Envy IOL offers a full visual range with high tolerance to dysphotopsia. Clinical trials in Canada showed excellent long-term outcomes, with 93% of patients reporting minimal visual disturbances and 94% experiencing little to no difficulty viewing close objects while achieving excellent distance vision without glasses. The lens features ActivSync Optic Intelligent Energy Distribution and ClearPath technology, enhancing vision in varying lighting conditions and reducing light scattering. Commercial availability in Canada is set for mid-June, with plans for additional regulatory approvals in the U.S. and Europe.
Bausch + Lomb (NYSE/TSX: BLCO) reported first-quarter 2024 results, with revenue reaching $1.099 billion, a GAAP net loss of $167 million, and an adjusted EBITDA of $180 million. The revenue grew by 18% as reported and 20% on a constant currency basis compared to the first quarter of 2023. The company experienced broad-based growth across all business segments and key franchises, with strong performance in Vision Care, Surgical, and Pharmaceuticals segments. The positive financial results were driven by growth in Daily SiHy lenses, LUMIFY, and eye vitamins, along with successful launches of MIEBO and XIIDRA. Bausch + Lomb also raised its full-year 2024 constant currency revenue growth guidance.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
